Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing FB-401, a live biotherapeutic product targeting atopic dermatitis and other inflammatory skin conditions. The company has no commercial revenue and operates as a pure R&D entity dependent on clinical trial outcomes and regulatory milestones. With a 7.34x current ratio and zero debt, the company maintains strong liquidity to fund ongoing clinical programs through near-term catalysts.
Forte operates as a clinical-stage biotech with no current revenue generation. The business model centers on advancing FB-401 through Phase 2/3 clinical trials, obtaining FDA approval, and either commercializing directly or partnering with larger pharmaceutical companies for distribution. Value creation depends entirely on clinical data readouts, regulatory approvals, and eventual market penetration in the $8-10 billion atopic dermatitis market. The company burns cash to fund R&D, with monetization contingent on successful clinical outcomes and regulatory milestones that could be 2-4 years away from generating revenue.
FB-401 clinical trial data readouts and interim analysis results for atopic dermatitis studies
FDA regulatory feedback, IND submissions, and breakthrough therapy designation decisions
Partnership announcements or licensing deals with major pharmaceutical companies
Patient enrollment milestones and trial timeline updates
Competitive clinical data from rival atopic dermatitis therapies (JAK inhibitors, biologics)
Cash runway updates and equity financing announcements
Binary clinical trial risk - FB-401 efficacy or safety failures in Phase 2/3 trials could render the entire platform worthless, with 342% one-year return reflecting high speculative premium that could reverse on negative data
Regulatory pathway uncertainty for live biotherapeutic products, which face evolving FDA guidance and manufacturing complexity compared to traditional small molecules
Competitive pressure from established atopic dermatitis therapies including Dupixent (Regeneron/Sanofi), JAK inhibitors (Rinvoq, Cibinqo), and emerging IL-13 inhibitors with proven efficacy data
Large pharmaceutical companies (Pfizer, Eli Lilly, AbbVie) dominating atopic dermatitis market with approved therapies and superior commercial infrastructure
Clinical differentiation challenge - FB-401 must demonstrate superior efficacy, safety, or convenience versus entrenched biologics to justify market share capture
Patent expiration risk and potential biosimilar competition if commercialization timeline extends beyond 2030
Cash burn rate of approximately $20-30 million annually with no revenue generation creates ongoing dilution risk through equity raises
Negative 53.3% ROA and 75.6% ROE reflect pre-revenue status but signal need for successful clinical outcomes to justify current $400 million market capitalization
Potential need for additional financing within 12-18 months depending on trial costs, which could be highly dilutive if raised during market volatility or after negative clinical data
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by scientific milestones rather than economic conditions. However, the company's ability to raise capital through equity offerings is moderately sensitive to risk appetite in public markets, which correlates with broader economic confidence. Institutional biotech investors maintain relatively stable allocation strategies across cycles.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress the net present value of future cash flows from potential drug approvals 3-5 years out, directly impacting valuation multiples for pre-revenue biotechs; (2) Elevated rates increase competition for capital as investors shift to fixed income, making equity financing more dilutive. The company's $0.0 debt means no direct financing cost impact, but valuation multiples contract as the risk-free rate rises.
Minimal direct credit exposure given zero debt and strong 7.34x current ratio. The company operates with equity financing and does not rely on credit markets for operations. However, broader credit market stress can indirectly impact ability to raise growth capital if biotech-focused venture and crossover funds face redemptions or reduced deployment capacity.
growth - Attracts high-risk, high-reward biotech specialists and momentum traders betting on binary clinical catalysts. The 342% one-year return and 155% six-month return demonstrate extreme momentum characteristics. Institutional holders are typically specialized healthcare funds with expertise in clinical trial analysis and regulatory pathways. Retail investors are drawn to lottery-ticket potential of 5-10x returns on positive Phase 3 data. Not suitable for value or income investors given pre-revenue status and no dividend potential.
high - Clinical-stage biotechs exhibit extreme volatility with 50-80% single-day moves common on data releases. The stock's 342% annual return demonstrates speculative trading dynamics. Beta likely exceeds 2.0x relative to broader market. Volatility spikes around clinical trial readout dates, FDA decision timelines, and financing announcements. Options markets typically price implied volatility at 80-120% for near-term expirations around catalyst dates.